Oncology

An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.

The new guidance released by HRSA proposes to improve oversight over the drug pricing program.

Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health.

The study published in JNCI has identified CES2 expression as a predictor of response to FOLFIRINOX.

While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.

Published in the journal Neurology, the study identified childhood cancer, along with hypertension and age, as a risk factor for recurrent stroke.

A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.

The Biosimilars Council wants CMS to hold back on Medicare Part B reimbursement for biosimilars.

An article published in the Journal of Clinical Oncology finds that survivorship care plans may not greatly improve patient satisfaction with their care.

The deadly nature of colorectal cancer merited attention in the Affordable Care Act, which called for eliminating cost-sharing for screening to prevent deaths. The future of colorectal screening, its cost-effectiveness, and a possible way to limit unneeded tests are the topic of a recent series of papers in The American Journal of Managed Care.

A trigger built in patient EHRs can avoid follow-up delays in those at risk for developing certain types of cancers, a JCO study shows.

Aetna and the University of Chicago Medicine kicked off a value-based oncology medical home model in July this year in an effort to transition from fee-for-service to value-based care.

The National Comprehensive Cancer Network has announced the development of another "price" calculator that will help stakeholders assess the relative "value" of available options.

The study published in Science Translational Medicine found that tissue stiffening in the breasts of obese women can drive the development of malignant disease.

There are many cost-related pieces in the grand picture of care that are devastating to families and patients, including copayments, hospital visit bills, transportation fees, and drug prices.

Conducted by researchers at the Memorial Sloan Kettering Cancer Center, phase 2 results from a basket trial evaluated the efficacy of vemurafenib on nonmelanoma BRaf V600-mutated cancers in 122 patients across 23 global centers.

Colorectal cancer screening involves balancing immediate harms with longer-term benefits; electronic medical record decision support may facilitate personalized benefit/harm assessment.

This supplement summarizes proceedings from the AJMC Oncology Stakeholders Summit, Spring 2015 series, at which experts gathered to discuss the evolving treatment landscape in oncology and the development of innovative payment models to help reduce the cost of care without sacrificing quality of care.

New resources are being directed toward precision medicine, particularly in cancer care. With that in mind, Evidence-Based Oncology, a publication of The American Journal of Managed Care, devotes its current issue to articles and commentaries on this growing field.

Evidence provided by a study published in The Lancet Oncology affirms that oral contraceptives provide long-term protection against endometrial cancer.

An article published in JAMA Oncology underscores the need for efforts to improve quality of life for cancer patients.

Analysis of results from the CHAARTED trial, published in the New England Journal of Medicine, has found that 6 cycles of chemotherapy (docetaxel) before androgen-deprivation therapy early in the treatment of metastatic prostate cancer significantly improved overall survival than treatment with ADT alone.

A multicollaborative study conducted for the National Cancer Institute has resulted in a tool called the Common Terminology Criteria for Adverse Events (PRO-CTCAE). PRO-CTCAE can help integrate the patient perspective into adverse event reporting.